ZD 6126

Drug Profile

ZD 6126

Alternative Names: ANG-453; ZD-6126

Latest Information Update: 07 Jul 2011

Price : $50

At a glance

  • Originator Angiogene Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 14 Feb 2005 A preclinical study has been added to the Cancer pharmacodynamics section
  • 03 Aug 2004 Preclinical studies in Solid tumours in the US - due to unexpected toxicity findings from phase II studies, ZD 6126 is now undergoing preclinical studies to explore scheduling options
  • 09 Oct 2003 Data presented at the 12th European Conference of Clinical Oncology (ECCO-2003) have been added to the pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top